⬆ $Protalix BioTherapeutics (PLX)$ - Protalix is a clinical and commercial pharmaceutical company using its proprietary ProCellEx plant-based expression system to pro duce thera... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/plx-first-quarter-update?utm_source=tiger_community By Zacks Small Cap Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/zacks-small-cap-research?utm_source=tiger_community On Protalix BioTherapeutics (PLX):- https://www.smartkarma.com/entities/protalix-biotherapeutics-inc?utm_source=tiger_community
Keep loading here by the thousands if you can. This is considered a cyclical stock hahah suddenly these plays are out of favor. Wait a while this goes to 15$Protalix BioTherapeutics(PLX)$
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.